AMRX Amneal Pharmaceuticals, Inc.
FY2025 10-K
Amneal Pharmaceuticals, Inc. (AMRX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 27, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of complex generic and branded pharmaceutical products focusing on high-barrier, high-value formulations
- • New product emphasis: Launch of five oncology biosimilars including Boncresa™ and Oziltus™ FDA-approved in Dec 2025, plus first complex inhalation aerosol generics from Ireland facility
Management Discussion & Analysis
- • Net cash from operating activities $340.0M in 2025 vs $295.1M in 2024; 15.2% increase but lower YoY excluding $52.4M prior litigation settlement
- • Net cash used in investing activities $112.3M in 2025 vs $63.0M in 2024; 78.2% increase due to higher capex and property deposits
Risk Factors
- • Tax Receivable Agreement (TRA) liability contingent $129.1M as of Dec 31, 2025 from basis adjustments under IRC Section 754
- • Geopolitical exposure not specified; no direct mention of macroeconomic or international risk in text
Financial SummaryXBRL
Revenue
$3.0B
Net Income
$72M
Gross Margin
36.9%
Operating Margin
13.1%
Net Margin
2.4%
ROE
-101.8%
Total Assets
$3.7B
EPS (Diluted)
$0.22
Operating Cash Flow
$340M
Source: XBRL data from Amneal Pharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Amneal Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.